Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and
Pharmacodynamics of NST-6179 in Adult Subjects with Intestinal Failure-Associated Liver Disease (IFALD)
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The prupose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in adult subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN).
-
Exploratory Study of the Impact of Lactobacillus rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
Scottsdale/Phoenix, Ariz.
The purpose of this study is to observe how the addition of Lactobacillus rhamnosus GG effects changes to the fecal microbiota related to PPI use in healthy individuals.
Contact Us for the Latest Status
Closed for Enrollment
-
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS) (EASE SBS 2)
Rochester, Minn.
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
-
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS) (EASE SBS 1)
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The primary purpose of this trial is to confirm the effectiveness of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome. Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
-
Changes in Gut Microbiota after Endoscopic Procedures for the Treatment of Obesity
Scottsdale/Phoenix, Ariz.,
Rochester, Minn.
The purpose of this study is to learn more about the effects of similar weight loss through caloric restriction, gastric reduction, and bypass of the proximal small intestines on gut microbiota and compare them to changes in the microbiome of obese subjects undergoing sham procedures and life-style modification.
-
Ex Vivo Evaluation of Total Bacterial Count in Adult Human Duodenal Fluid
Scottsdale/Phoenix, Ariz.
The purpose of this study is to develope a rapid lab test for counting total bacteria in human intestinal fluid collected by aspiration from the duodenal section of the small intestine.
-
Weight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial Overgrowth
Scottsdale/Phoenix, Ariz.
The potential role of Small bowel bacterial overgrowth (SBBO) in weight loss occurring in patients with PD has not previously been examined. Our hypothesis is that SBBO is an important contributor to the development of weight loss in individuals with Parkinson's disease. The investigators propose to 1) examine the role of SBBO in weight loss occurring in patients with PD and 2) determine the response to its treatment with a poorly absorbed antibiotic. The investigators propose to perform a prospective, observational case-control study with an open-label therapeutic component. Cases will be defined as those PD patients who've experienced significant weight loss while Controls will be defined as those PD patients who have not experienced significant weight loss.
.